Compare Incyte Corporation (INCY) vs US Global Jets ETF (JETS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs US Global Jets ETF — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while US Global Jets ETF trades at $27.16 (market cap $878.48M). The key difference: Incyte Corporation is far larger — about 26× US Global Jets ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and US Global Jets ETF for 26 Days on average.
| INCY | JETS | |
|---|---|---|
Market Cap | $22.85B | $878.48M |
Volume | 1,927,029 | 4,465,925 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $33.53 |
52-Week Low | $83.80 | $23.64 |
Typical Hold Time | 33 Days | 26 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
JETS (U.S. Global Jets ETF) trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
The outlook remains challenging with fuel cost volatility and competitive ETF alternatives presenting risks. However, oversold technical conditions and potential travel demand recovery offer selective opportunities for investors seeking airline exposure. Key catalysts include fuel price stabilization and holiday travel trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
